Acrux (ASX:ACR) shares double as it banks A$5.4m from an amendment to its licensing deal for Lenzetto!

Acrux will receive an upfront payment plus milestones within two years of launch, providing runway for its Female Testosterone push.

Acrux (ASX:ACR) has just amended its long-running licensing deal with Hungarian pharma giant Gedeon Richter to receive A$5.4 million in upfront, regulatory and commercial milestones tied to bringing Estradiol spray Lenzetto into the Australian market. Payments will flow within two years of launch.

For a company of Acrux’s size, A$5.4 million is meaningful non-dilutive cash that lands at a useful moment, with management openly flagging it as fuel for the next priority, the Female Testosterone product moving towards market.

The other half of the story is the demand side. Australia has been short of Menopause Hormone Therapy products for years, with patients and prescribers swapping brands as supply has come and gone. Lenzetto is not a new molecule globally. It already sits in more than 40 countries and did EUR 50 million of sales for Richter in 2025.

That combination, a known product, a partner already commercialising it offshore, and a domestic market starved of options, is what makes today’s announcement more than a routine licensing update.

Why the A$5.4m is more interesting than it first looks

The milestone structure is more important than it may appear at first glance. Acrux receives an upfront payment, then regulatory milestones on registration, then commercial milestones as Lenzetto actually starts selling in Australia. That means cash flows are spread across the next two years rather than being one lumpy hit.

For a specialty pharma with no big balance sheet to lean on, staged milestones from a EUR 4.8 billion market-cap partner are about as clean as funding gets. No raise, no dilution, no warrants. Just contracted payments against a product Richter already sells in dozens of markets.

Our take is that the real value isn’t just the A$5.4 million itself and the injection of it, but also the extended time it buys to push the Female Testosterone program forward without going back to shareholders.

Lenzetto is a known product walking into a hungry market

Lenzetto uses Acrux’s Patchless Patch technology, originally developed at Monash University, to deliver Estradiol through the skin without an adhesive patch. For patients, that means discrete, consistent dosing for symptoms like hot flushes after menopause.

The Australian MHT shortage is well documented, with PBS-listed alternatives going in and out of supply for several years now. Bringing in a product that already has EUR 50 million of global sales and an established manufacturing footprint is a far lower-risk launch than starting from scratch.

The risk to flag is timing. Regulatory approval and TGA listing decisions are not in Acrux’s hands, and the commercial milestones only flow once Richter is actually selling product locally. Slippage in either step pushes payments to the right.

What this deal signals about the next chapter

Management has been clear that the Female Testosterone product is the next big swing for Acrux. That program needs cash, and today’s deal is essentially Richter paying part of the bill in exchange for a product Acrux already developed years ago.

It is the kind of capital recycling story that small specialty pharma names rarely execute well. Acrux now has a credible argument that legacy products can keep funding new ones, which changes how investors should think about the cash burn profile going forward.

The Takeaway For Investors

The A$5.4 million is not transformational on its own, but it is exactly the kind of deal that buys the company optionality. The Female Testosterone program is the real lever for re-rating this stock, and today’s announcement makes the path there a bit less reliant on capital markets.

We will be watching two things over the next 12 months. First, the timing of the regulatory milestone, which signals when commercial payments start flowing. Second, any update on the Female Testosterone clinical and regulatory timeline, because that is where the long-term value sits. For more coverage of small-cap ASX specialty pharma names, readers can browse our archive at stocksdownunder.